Carlyle Secured Lending, Inc. (CGBD)
NASDAQ: CGBD · Real-Time Price · USD
13.87
+0.04 (0.33%)
At close: Aug 12, 2025, 4:00 PM
13.88
+0.02 (0.11%)
After-hours: Aug 12, 2025, 4:10 PM EDT
Lumos Pharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover Lumos Pharma stock have a consensus rating of "Hold" and an average price target of $14.63, which forecasts a 5.52% increase in the stock price over the next year. The lowest target is $14 and the highest is $15.
Price Target: $14.63 (+5.52%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Lumos Pharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 2 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 3 | 3 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Hold Maintains $14 → $15 | Hold | Maintains | $14 → $15 | +4.58% | Aug 11, 2025 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $13 → $15 | Hold → Buy | Upgrades | $13 → $15 | +8.19% | Jul 25, 2025 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jul 17, 2025 |
| Oppenheimer | Oppenheimer | Hold Maintains $17 → $15 | Hold | Maintains | $17 → $15 | +8.19% | May 8, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $14 → $13 | Hold | Maintains | $14 → $13 | -6.24% | May 8, 2025 |
Financial Forecast
Revenue This Year
265.78M
from 232.59M
Increased by 14.27%
Revenue Next Year
281.66M
from 265.78M
Increased by 5.97%
EPS This Year
1.63
from 1.58
Increased by 3.49%
EPS Next Year
1.66
from 1.63
Increased by 1.51%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 278.2M | 297.9M | 293.2M |
| Avg | 265.8M | 281.7M | 284.8M |
| Low | 251.9M | 257.7M | 273.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 19.6% | 12.1% | 4.1% |
| Avg | 14.3% | 6.0% | 1.1% |
| Low | 8.3% | -3.0% | -2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.70 | 1.75 | 1.73 |
| Avg | 1.63 | 1.66 | 1.68 |
| Low | 1.55 | 1.55 | 1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 8.0% | 7.5% | 4.7% |
| Avg | 3.5% | 1.5% | 1.7% |
| Low | -1.7% | -5.1% | -2.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.